Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Bone Marrow Transplantation

• Publication date

  2005-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/sj.bmt.1704929PMID 15806135
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial.

  2004cited by this paper
• Improved survival in steroid‐refractory acute graft versus host disease after non‐myeloablative allogeneic transplantation using a daclizumab‐based strategy with comprehensive infection prophylaxis

  2004cited by this paper
• Both donor and recipient NOD2/CARD15 mutations associate with transplant-related mortality and GvHD following allogeneic stem cell transplantation.

  2004cited by this paper
• Tumor necrosis factor-alpha blockade for the treatment of acute GVHD.

  2004cited by this paper
• Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation.

  2004cited by this paper
• Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents.

  2003cited by this paper
• Cerebral toxoplasmosis following etanercept treatment for idiophatic pneumonia syndrome after autologous peripheral blood progenitor cell transplantation (PBPCT)

  2003cited by this paper
• Infliximab for the Treatment of Severe Steroid Refractory Acute Graft-versus-host Disease in Three Patients after Allogeneic Hematopoietic Transplantation

  2003cited by this paper
• The safety of biologic agents in early rheumatoid arthritis.

  2003cited by this paper
• Infliximab for steroid‐refractory acute GVHD: A case series

  2003cited by this paper
• Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study.

  2003cited by this paper
• Treatment of acute graft versus host disease with low dose-alternate day anti-thymocyte globulin.

  2002cited by this paper
• Psoralen and ultraviolet A irradiation (PUVA) as therapy for steroid-resistant cutaneous acute graft-versus-host disease.

  2002cited by this paper
• Etanercept (Enbrel) administration for idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation.

  2002cited by this paper
• Invasive pulmonary aspergillosis following bone marrow transplantation: risk factors and diagnostic aspect.

  2002cited by this paper
• Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors.

  2002cited by this paper
• A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease.

  2002cited by this paper
• Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease.

  2002cited by this paper
• Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation

  2002cited by this paper
• Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment.

  2002cited by this paper
• Thrombotic thrombocytopenic purpura after allogeneic stem cell transplantation: a survey of the European Group for Blood and Marrow Transplantation (EBMT)

  2002cited by this paper
• Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL.

  2001cited by this paper
• SIROLIMUS (RAPAMYCIN) FOR THE TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE1

  2001cited by this paper
• Chronic graft-versus-host disease after allogeneic blood stem cell transplantation.

  2001cited by this paper
• Treatment of steroid refractory acute and chronic graft‐versus‐host disease with daclizumab

  2001cited by this paper
• Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFα antibody

  2001cited by this paper
• Tumor necrosis factor-alpha neutralization reduces lung injury after experimental allogeneic bone marrow transplantation.

  2000cited by this paper
• Etanercept in graft-versus-host disease

  2000cited by this paper
• Extracorporeal photochemotherapy in the treatment of severe steroid-refractory acute graft-versus-host disease: a pilot study.

  2000cited by this paper
• An old drug for a new disease: pentostatin (Nipent) in acute graft-versus-host disease.

  2000cited by this paper
• Treatment of Steroid-Resistant Acute Graft-Versus-Host Disease with Rabbit Antithymocyte Globulin

  2000cited by this paper
• Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients

  1998cited by this paper
• Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease.

  1997cited by this paper
• 1994 Consensus Conference on Acute GVHD Grading.

  1995cited by this paper
• TREATMENT OF ACUTE GRAFT‐VERSUS-HOST DISEASE WITH METHYLPREDNISOLONE AND CYCLOSPORINE WITH OR WITHOUT AN ANTI‐INTERLEUKIN-2 RECEPTOR MONOCLONAL ANTIBODY: A Multicenter Phase III Study

  1995cited by this paper
• Treatment of steroid-resistant acute graft-versus-host disease with an anti-IL-2-receptor monoclonal antibody (BT 563) in children who received T cell-depleted, partially matched, related bone marrow transplants.

  1994cited by this paper
• Predictive factors for chronic graft-versus-host disease after histocompatible sibling donor bone marrow transplantation.

  1994cited by this paper
• Treatment of GVHD--TNF-antibodies and related antagonists.

  1993cited by this paper
• Phase I-II trial of a monoclonal anti-tumor necrosis factor alpha antibody for the treatment of refractory severe acute graft-versus-host disease.

  1992cited by this paper
• Anti-interleukin-2 receptor monoclonal antibody (BT 563) in the treatment of severe acute GVHD refractory to systemic corticosteroid therapy.

  1992cited by this paper
• Monoclonal anti TNF alpha antibody in the treatment of acute GvHD refractory both to corticosteroids and anti IL-2 R antibody.

  1991cited by this paper
• Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome.

  1990cited by this paper
• Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation.

  1990cited by this paper
• Treatment of corticosteroid resistant acute graft-versus-host disease by in vivo administration of anti-interleukin-2 receptor monoclonal antibody (B-B10)

  1990cited by this paper
• Bone marrow transplantation.

  1977cited by this paper

• Graft-Versus-Host Disease Mouse Models: A Clinical-Translational Perspective.

  2025cites this paper
• Ruxolitinib plus basiliximab therapy for steroid-refractory acute graft-versus-host disease in unrelated cord blood transplantation: a large-scale study.

  2024cites this paper
• Second-line therapy for patients with steroid-refractory aGVHD: systematic review and meta-analysis of randomized controlled trials

  2023cites this paper
• Basiliximab for steroid‐refractory acute graft‐versus‐host disease: A real‐world analysis

  2022cites this paper
• Lyell-Like Acute Graft-Versus-Host-Disease

  2021cites this paper
• Immunomodulatory Therapies for the Treatment of Graft-versus-host Disease

  2021cites this paper
• Meta-Analysis of Interleukin-2 Receptor Antagonists as the Treatment for Steroid-Refractory Acute Graft-Versus-Host Disease

  2021influential citation
• Treatment and unmet needs in steroid-refractory acute graft-versus-host disease

  2020cites this paper
• Prognostic factors and long‐term follow‐up of basiliximab for steroid‐refractory acute graft‐versus‐host disease: Updated experience from a large‐scale study

  2020cites this paper
• Nuclear factor-κB1 and MicroRNA-146a polymorphisms and risk of acute graft versus host disease post allogeneic stem cell transplantation.

  2019cites this paper
• Wirksamkeit und Sicherheit einer intravesikalen Cidofovir-Therapie bei BK-Virus-assoziierter hämorrhagischer Zystitis nach allogener Stammzelltransplantation

  2019cites this paper
• Etanercept as Treatment of Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric Patients.

  2019cites this paper
• EBMT—NIH—CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment

  2018cites this paper
• Poor prognosis in patients with steroid refractory acute graft versus host disease treated with etanercept: a multi-centre analysis

  2018cites this paper
• Combining therapeutic antibodies using basiliximab and etanercept for severe steroid-refractory acute graft-versus-host disease: A multi-center prospective study

  2017cites this paper
• Etanercept for steroid-refractory acute graft-versus-host disease: A single center experience

  2017cites this paper
• CD25 Blockade Delays Regulatory T Cell Reconstitution and Does Not Prevent Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation.

  2017cites this paper
• A phase 3 randomized trial comparing inolimomab vs usual care in steroid-resistant acute GVHD.

  2017cites this paper
• Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry)

  2017cites this paper
• Tocilizumab for steroid refractory acute graft-versus-host disease

  2016cites this paper
• Inolimomab in steroid-resistant aGvHD 1 A phase III randomized trial comparing Inolimomab vs . Usual care in steroid-resistant acute GVHD

  2016cites this paper
• J Turk Acad Dermatol 2016; 10 (1): 16101r1

  2016cites this paper
• Understanding graft-versus-host disease. Preliminary findings regarding the effects of exercise in affected patients.

  2015cites this paper
• This information is current as Cytokines in Graft-versus-Host Disease

  2015cites this paper
• Off-Label Dermatological Uses of Etanercept Treatment

  2015cites this paper
• Extracorporeal photopheresis for paediatric patients experiencing graft-versus-host disease (GVHD).

  2014cites this paper
• Advances in the treatment of acute graft-versus-host disease

  2013cites this paper
• Documentation of off-label use of biologics in Rheumatoid Arthritis

  2013cites this paper
• Recent compounds for immunosuppression and experimental therapies for acute graft-versus-host disease.

  2013cites this paper
• Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid‐refractory, grade III–IV acute graft‐versus‐host disease

  2013cites this paper
• Extracorporeal photopheresis for the treatment of acute and chronic graft‐versus‐host disease in adults and children: best practice recommendations from an Italian Society of Hemapheresis and Cell Manipulation (SIdEM) and Italian Group for Bone Marrow Transplantation (GITMO) consensus process

  2013cites this paper
• Treatment of severe steroid resistant acute GVHD with mesenchymal stromal cells (MSC).

  2013cites this paper
• Treatment options for graft-versus-host disease

  2013cites this paper
• Recent progress in managing graft-versus-host disease and viral infections following allogeneic stem cell transplantation.

  2012cites this paper
• Secondary treatment of acute graft-versus-host disease: a critical review.

  2012cites this paper
• Treatment of steroid-resistant acute graft-versus-host disease

  2012cites this paper
• BCSH/BSBMT Guideline: Diagnosis and Management of Chronic Graft- versus-Host Disease

  2012cites this paper
• Diagnosis and management of acute graft‐versus‐host disease

  2012cites this paper
• First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation.

  2012cites this paper
• Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010

  2011cites this paper
• The use of monoclonal antibodies for the treatment of graft-versus-host disease following allogeneic stem cell transplantation

  2011cites this paper
• Etanercept for steroid-refractory acute graft versus host disease following allogeneic hematopoietic stem cell transplantation

  2011cites this paper
• [Use of monoclonal antibodies in prophylaxis and treatment of acute and chronic graft-versus-host disease in 2011].

  2011cites this paper
• Leczenie sterydoopornej ostrej choroby przeszczep przeciwko gospodarzowi

  2011cites this paper
• Place des anticorps monoclonaux dans la prophylaxie et le traitement de la maladie aiguë et chronique du greffon contre l’hôte en 2011

  2011cites this paper
• Clinical and epidemiological research

  2011cites this paper
• Tumor necrosis factor polymorphism affects transplantation outcome in patients with myelodysplastic syndrome but not in those with chronic myelogenous leukemia, independent of the presence of HLA-DR15.

  2010cites this paper
• [Etanercept. Other indications].

  2010cites this paper
• Second allo-SCT from a different donor can improve severe steroid-resistant gut GVHD

  2010cites this paper
• Etanercept. Otras indicaciones

  2010cites this paper
• Graft-versus-host disease

  2010cites this paper
• Inflammatory Cytokine Inhibition with Combination Daclizumab and Infliximab for Steroid Refractory Acute Graft-Versus-Host Disease

  2010cites this paper
• Immunotherapy following hematopoietic stem cell transplantation: potential for synergistic effects.

  2010cites this paper
• Treatment of graft-versus-host disease with monoclonal antibodies and related fusion proteins

  2010cites this paper
• Chapter 20 – Invasive fungal infections in cancer patients

  2009cites this paper
• Manifestations and Treatment of Acute Graft‐versus‐Host Disease

  2009cites this paper
• Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009

  2009cites this paper
• Bone marrow transplantation: new approaches to immunosuppression and management of acute graft-versus-host disease

  2009cites this paper
• Pharmaceutical and cellular strategies in prophylaxis and treatment of graft-versus-host disease.

  2009cites this paper
• Daclizumab as useful treatment in refractory acute GVHD: a paediatric experience

  2009cites this paper
• CD25 Blockade protects T Cells from Activation‐induced Cell Death (AICD) via Maintenance of TOSO Expression

  2009cites this paper
• Effect of Etanercept on Steroid Refractory Graft-versus-host Disease in Children

  2009cites this paper
• The Role of Oral Beclometasone Dipropionate in the Treatment of Gastrointestinal Graft-versus-Host Disease

  2009cites this paper
• Current and novel therapies in acute GVHD.

  2008cites this paper
• Acute Graft-versus-Host Disease

  2008cites this paper
• 89 – Protein kinase antagonists as therapeutic agents for immunological and inflammatory disorders

  2008cites this paper
• Novel drugs for the prevention and treatment of acute GVHD.

  2008cites this paper
• Low-dose MTX for the treatment of acute and chronic graft-versus-host disease in children

  2008cites this paper
• Enteral budesonide in treatment for mild and moderate gastrointestinal chronic GVHD

  2008cites this paper
• Uso de fármacos biológicos en dermatosis fuera de la indicación aprobada. Segunda parte: etanercept, efalizumab, alefacept, rituximab, daclizumab, basiliximab, omalizumab y cetuximab

  2008cites this paper
• Current and future approaches for control of graft-versus-host disease

  2008cites this paper
• [Off-label use of biologic agents in the treatment of dermatosis, part 2: etanercept, efalizumab, alefacept, rituximab, daclizumab, basiliximab, omalizumab, and cetuximab].

  2008cites this paper
• Role Of Cytokines In The Immunopathogenesis Of Graft-versus-host Disease [papel Das Citocinas Na Imunopatogênese Da Doença Do Enxerto Contra O Hospedeiro]

  2008cites this paper
• Infectious complications associated with immunomodulating monoclonal antibodies used in the treatment of hematologic malignancy.

  2008cites this paper
• Graft-versus-host disease and immunosuppression

  2008cites this paper
• 2008for the treatment of rheumatic diseases, Updated consensus statement on biological

  2008cites this paper
• Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008

  2008cites this paper
• Sclerodermatous graft‐versus‐host disease: clinical spectrum and therapeutic challenges

  2007cites this paper
• Graft-versus-Host Disease : The Pesky Fly in the Ointment

  2007cites this paper
• Favorable response to human adipose tissue-derived mesenchymal stem cells in steroid-refractory acute graft-versus-host disease.

  2007cites this paper
• High incidence of invasive aspergillosis associated with intestinal graft-versus-host disease following nonmyeloablative transplantation.

  2007cites this paper
• Risk assessment in haematopoietic stem cell transplantation: GvHD prevention and treatment.

  2007cites this paper
• Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2).

  2007cites this paper
• Serum soluble TNF receptor I and II levels correlate with disease activity in IBD patients

  2007cites this paper
• for the treatment of rheumatic diseases, 2006 Updated consensus statement on biological agents

  2007cites this paper
• Advances in the understanding of acute graft‐versus‐host disease

  2007cites this paper
• [Role of monoclonal antibodies in the treatment of acute graft versus host disease].

  2007cites this paper
• Advancesintheunderstandingofacutegraft-versus-hostdisease

  2007cites this paper
• Mucosal graft-vs-host disease.

  2007cites this paper
• Human adipose tissue‐derived mesenchymal stromal cells as salvage therapy for treatment of severe refractory acute graft‐vs.‐host disease in two children

  2007cites this paper
• Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft‐versus‐host disease following allogeneic hematopoietic stem cell transplantation

  2007cites this paper
• Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007

  2007cites this paper
• Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006

  2006cites this paper
• Biologics in the prevention and treatment of graft rejection

  2006cites this paper
• Combination antithymocyte globulin and soluble TNFα inhibitor (etanercept) +/− mycophenolate mofetil for treatment of steroid refractory acute graft-versus-host disease

  2006cites this paper
• Acute Graft-Versus-Host Disease

  2006cites this paper
• Low-dose methotrexate as salvage therapy for refractory graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation.

  2006cites this paper
• Daclizumab for children with corticosteroid refractory graft-versus-host disease

  2006cites this paper
• Off-label uses of biologic agents in dermatology: a 2006 update.

  2006cites this paper
• Replacement of calcineurin inhibitors with daclizumab in patients with transplantation-associated microangiopathy or renal insufficiency associated with graft-versus-host disease

  2006cites this paper